Pyrimidine mPGES-1 Inhibitors With Better Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory drugs, such as NSAIDs and COX-2 inhibitors, cause gastric mucosal injuries and increase cardiovascular risks due to non-selective inhibition of the prostaglandin biosynthesis pathway, while existing mPGES-1 inhibitors may have limitations in solubility and absorption.
Innovation Solution
Development of pyrimidine derivatives substituted with an m-phenylene group, represented by general formula (I), which exhibit potent mPGES-1 inhibitory action, high solubility, and rapid absorption upon oral administration, providing effective treatment for inflammation and pain without gastric side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs inhibit COX in the prostaglandin biosynthesis pathway, then anti-inflammatory activity is improved, but gastric mucosal injury increases
Solution Approach 1:
The patent segments the prostaglandin biosynthesis pathway by specifically targeting the mPGES-1 enzyme at the final step of PGE2 synthesis, rather than inhibiting COX enzymes upstream. This segmentation allows selective inhibition of inflammatory prostaglandins while preserving gastric protective prostaglandins, thereby maintaining anti-inflammatory activity while reducing gastric mucosal injury
Solution Approach 2:
The patent applies local quality by designing mPGES-1 inhibitors that selectively act on the enzyme in inflammatory tissues where mPGES-1 is induced, while leaving COX-1 and COX-2 enzymes unaffected in gastric mucosa. This localized action at the specific enzymatic step achieves anti-inflammatory effects without the broad suppression that causes gastric damage
2Reliability
If COX-2 inhibitors selectively suppress PGI2 production, then anti-inflammatory activity is improved, but thrombosis risk increases
Solution Approach 1:
The patent segments the prostaglandin pathway at the mPGES-1 step, which is specifically induced in inflammatory tissues. This segmentation allows selective inhibition of PGE2 production in inflamed areas while preserving COX-1-mediated thromboxane A2 synthesis, thereby achieving anti-inflammatory effects without increasing thrombosis risk
Solution Approach 2:
The patent changes the target parameter from COX enzyme inhibition to mPGES-1 enzyme inhibition. By targeting the downstream mPGES-1 enzyme that is specifically induced during inflammation, the drug achieves selective PGE2 suppression without affecting the balance between vasodilatory and vasoconstrictive prostanoids, thus avoiding thrombosis risk
3Reliability
If existing mPGES-1 inhibitors are used, then PGE2 production is suppressed, but solubility and absorption are limited
Solution Approach 1:
The patent changes the chemical and physical parameters of the mPGES-1 inhibitor molecules to improve solubility and absorption. By modifying molecular structure and physicochemical properties while maintaining enzymatic inhibition capability, the patent achieves both effective PGE2 suppression and improved bioavailability
Solution Approach 2:
The patent employs composite molecular structures that combine pharmacophoric elements for mPGES-1 binding with structural features that enhance solubility and absorption. These composite molecular designs integrate both efficacy and pharmacokinetic optimization
Data Source
AI summary
A compound of the formula (I) or a salt thereof (R represents methyl group or fluorine atom) having an mPGES-1 inhibitory activity and useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of such diseases as inflammation, pain, or rheumatism.